Antimicrobial and clinical effect of linezolid (ZYVOX®), a new class of synthetic antibacterial drug

Folia Pharmacologica Japonica

Volumn 120, Issue 4, 2002, Pages 245-252

  Irinoda, Kazuhiko ^a   Nomura, Syunji ^a   Hashimoto, Munehiro ^a  

^a Global Development Japan   (Japan)

Author keywords

Linezolid; Oxazolidinone; Protein synthesize inhibition; VRE; ZYVOX

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CHLORAMPHENICOL; LINEZOLID; MACROLIDE; METHIONINE TRANSFER RNA; METICILLIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PROTEIN SYNTHESIS INHIBITOR; RIBOSOME RNA; TEICOPLANIN; TETRACYCLINE; TRANSFER RNA; VANCOMYCIN;

ABSCESS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BACTERIOSTASIS; BETA HEMOLYTIC STREPTOCOCCUS; CLINICAL TRIAL; CROSS RESISTANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DNA BINDING; DRUG EFFICACY; DRUG PROTEIN BINDING; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; HUMAN; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW; RIBOSOME SUBUNIT; RNA TRANSLATION; SOFT TISSUE INFECTION; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICE; OXAZOLIDINONES;

EID: 0036389308     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.120.245     Document Type: Review

References (19)

1. Shinabarger D: Mechanism of action of the oxazolidinone antibacterial agent. Exp Opin Invest Drugs 8(8), 1195-1202 (1999)
2. Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, Dunyak DS, Demyan WF and Buysse JM: Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 41 (10), 2132-2136 (1997)
3. Lin AH, Murray RW, Vidmar TJ and Marotti KR: The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with the binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 41 (10), 2127-2131 (1997)
4. Swaney SM, Aoki H, Ganoza MC and Shinabarger DL: The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 42 (12), 3251-3255 (1998)
5. Fernandez-Munoz R, Monro RE, Torres-Pinedo R and Vazquez D: Substrate- and antibiotic-binding sites at the peptidyl-transferase centre of Escherichia coli ribosomes. Studies on the chloramphenicol, lincomycin, and erythromycin sites. Eur J Biochem 23, 185-193 (1971)
6. Matassova NB, Rodnina MV, Endermann R, Kroll HP, Pleiss U, Wild H and Wintermeyer W: Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA 5(7), 939-946 (1999)
7. Burghardt H, Schimz KL and Muller M: On the target of a novel class of antibiotics, oxazolidinones, active against multidrug-resistant Gram-positive bacteria. FEBS Lett 425, 40-44 (1998)
8. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, Hutchinson DK, Barbachyn MR and Brickner SJ: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 40(4), 839-845 (1996)
9. Swaney SM, Shinabarger DL, Schaadt RD, Bock JH, Slightom JL and Zurenko GE: Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA [Abstract C-104]. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24-27, San Diego (1998)
10. Diekema DJ and Jones RN: Oxazolidinones. Drugs 59(1) 7-16 (2000)
11. Eliopoulos GM, Wennersten CB, Gold HS and Moellering RC, Jr.: In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 40(7) 1745-1747 (1996)
12. Jones RN, Johnson DM and Erwin ME: In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 40(3) 720-726 (1996)
13. Rybak HJ, Cappelletty DM, Moldovan T, Aeschlimann JR and Kaatz GW: Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperezolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against Staphylococcus aureus, Coagulase-Negative Staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 42 (3) 721-724 (1998)
14. Ford CW, Hamel JC, Wilson DM, Moerman JK, Stapert D, Yancey RJ, Jr, Hutchinson DK, Barbachyn MR and Brickner SJ: In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother 40(6) 1508-1513 (1996)
15. Birmingham MC, Zimmer GS, Hafkin B, Todd WM, Batts D, Flavin S, Rayner C, Weich KE, Smith PF, Root JD, et al: Outcomes with linezolid (LZD) from an ongoing compassionate use(CU) trial of patients with significant, resistant, gram-positive infections [Abstract 1098]. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-29, San Francisco (1999)
16. Davies J: Inactivation of antibiotics and the dissemination of resistance genes. Science 264, 375-382 (1994)
17. Nikaido H: Prevention of drug access to bacterial targets: Permeability barriers and active efflux. Science 264, 382-388 (1994)
18. Spratt BG: Resistance to antibiotics mediated by target alterations. Science 264, 388-393 (1994)